Business Description
![Jazz Pharmaceuticals PLC Jazz Pharmaceuticals PLC logo](https://static.gurufocus.com/logos/0C00000PW8.png?14)
Jazz Pharmaceuticals PLC
NAICS : 325412
SIC : 2834
ISIN : IE00B4Q5ZN47
Compare
Compare
Traded in other countries / regions
JAZZ.USAJ7Z.GermanyJAZZ.Mexico IPO Date
2007-06-01Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.31 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 1.57 | |||||
Debt-to-EBITDA | 4.96 | |||||
Interest Coverage | 1.94 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 1.35 | |||||
Beneish M-Score | -2.7 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.4 | |||||
3-Year EBITDA Growth Rate | 13.8 | |||||
3-Year EPS without NRI Growth Rate | -15.5 | |||||
3-Year FCF Growth Rate | 16.5 | |||||
3-Year Book Growth Rate | -2.7 | |||||
Future 3-5Y EPS without NRI Growth Rate | 47.21 | |||||
Future 3-5Y Total Revenue Growth Rate | 6.16 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 68.99 | |||||
9-Day RSI | 62.55 | |||||
14-Day RSI | 57.55 | |||||
6-1 Month Momentum % | -12.55 | |||||
12-1 Month Momentum % | -18.05 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.27 | |||||
Quick Ratio | 1.9 | |||||
Cash Ratio | 1.16 | |||||
Days Inventory | 565.65 | |||||
Days Sales Outstanding | 62.21 | |||||
Days Payable | 93.87 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.5 | |||||
Shareholder Yield % | 1.38 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 89.53 | |||||
Operating Margin % | 14.23 | |||||
Net Margin % | 8.61 | |||||
FCF Margin % | 25.59 | |||||
ROE % | 9.3 | |||||
ROA % | 2.94 | |||||
ROIC % | 8.46 | |||||
ROC (Joel Greenblatt) % | 49.81 | |||||
ROCE % | 5.26 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 23 | |||||
Forward PE Ratio | 5.58 | |||||
PE Ratio without NRI | 12.91 | |||||
Shiller PE Ratio | 23.69 | |||||
Price-to-Owner-Earnings | 20.1 | |||||
PS Ratio | 2 | |||||
PB Ratio | 1.9 | |||||
Price-to-Free-Cash-Flow | 7.68 | |||||
Price-to-Operating-Cash-Flow | 7.27 | |||||
EV-to-EBIT | 20.81 | |||||
EV-to-Forward-EBIT | 9.1 | |||||
EV-to-EBITDA | 9.32 | |||||
EV-to-Forward-EBITDA | 7.01 | |||||
EV-to-Revenue | 2.83 | |||||
EV-to-Forward-Revenue | 2.67 | |||||
EV-to-FCF | 11.06 | |||||
Price-to-Projected-FCF | 0.58 | |||||
Price-to-Median-PS-Value | 0.47 | |||||
Earnings Yield (Greenblatt) % | 4.81 | |||||
FCF Yield % | 13.98 | |||||
Forward Rate of Return (Yacktman) % | 7.9 |